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Presence of low levels of Francisella tularensis in the Washington D.C. area, September 30,
2005.
CDC has become aware that from September 24th through September 25th environmental air 
monitors in SW Washington D.C., more specifically the Capitol Mall area, signaled the low level 
presence of Francisella tularensis, the bacterium that causes Tularemia, also known as “rabbit 
fever.”
At this time, public health agencies have no reports of any related human or animal illnesses.
This announcement is a precautionary measure to assure that clinicians are aware of the 
situation and are able to recognize, test, and report any suspected cases to the appropriate 
medical and public health authorities.
This is a national alert because the Capitol Mall area is a highly-trafficked tourist destination, and 
on Saturday, September 24th, was the site of several very well attended outdoor events.
Clinical Presentations
The clinical presentations most likely to occur after an aerosol exposure to F. tularensis are 
pneumonic, oculoglandular and oropharyngeal. The usual incubation period is 3-5 days, but in 
rare instances can be longer. The disease is not communicable from person to person and can 
be effectively treated with readily available antimicrobials.
Preliminary Case Definition
Onset from Monday September 26 through October 5 of an acute febrile illness associated with at 
least one of the following:
* conjunctivitis with preauricular lymphadenopathy (oculoglandular)
* stomatitis or pharygitis or tonsillitis and cervical lymphadenopathy (oropharyngeal)
* cough, shortness of breath, pleuritic chest pain (pneumonic),
which is not otherwise explained in a resident or visitor to the National Capitol Region on 
Saturday or Sunday, September 24-25.
Human Diagnostic Specimens
Clinical specimens may include:
* Bronchial/tracheal washes or aspirates, sputum, trans-thoracic lung aspirates, or pleural 
fluid collection
* Swabs of visible lesions or affected areas (e.g., conjunctiva or pharynx)
Aspirates from lymph nodes
* Whole blood or blood cultures are acceptable specimens, but are generally positive in cases 
of severe illness only.
Laboratory Testing (Culture)
Microbiology laboratory personnel should be alerted when F. tularensis is clinically suspected, so 
that appropriate laboratory precautions can be taken.
F. tularensis is a fastidious, slow-growing organism that requires cysteine for growth.
F. tularensis may be cultured on the following:
* cysteine supplemented agar including chocolate agar (CA)
* cysteine heart agar with 9% chocolatized blood (CHAB)
* buffered charcoal yeast extract (BYCE)
* Thayer-Martin agar
Culture plates should be held for 5-7 days at 35-370C (C02 is acceptable) and checked for 
growth daily.
F. tularensis can be isolated from nutrient enriched specimens (tissues) on sheep blood agar 
(SBA), but the organism will usually fail to thrive with passage on SBA. Growth on CHAB 
provides for presumptive identification of F. tularensis as the organism shows characteristic 
growth on this media (green, opalescent, raised, shiny colonies at 24-48 hours).
Note: Specimens for recovery of live bacteria, should be collected before antibiotics are 
administered
Prophylaxis
CDC does not recommend mass or targeted prophylaxis at this time because:
* the usual incubation period has passed without an increase in suspicious illnesses in the
area, and air sampling since September 25th has been negative
* infection is readily treatable and generally has a low mortality rate with medical care




Streptomycin, 1g IM twice daily 
Gentamicin, 5 mg/kg IM or IV once da ily !
Alternative choices:
Doxycycline, 100 mg IV twice daily 
Ciprofloxacin, 400 mg IV twice da ily !
Children
Preferred choices:
Streptomycin, 15 mg/kg IM twice daily (should not exceed 2 gm/d)
Gentamicin, 2.5 mg/kg IM or IV 3 times da ily !
Alternative choices:
Doxycycline,
If weight >= 45 kg, 100 mg IV 
If weight < 45 kg, give 2.2 mg/kg IV twice daily 
Ciprofloxacin, 15 mg/kg IV twice da ily !
Pregnant Women
Preferred choices:
Gentamicin, 5 mg/kg IM or IV once da ily !
Streptomycin, 1 g IM twice daily
Alternative choices:
Doxycycline, 100 mg IV twice daily 
Ciprofloxacin, 400 mg IV twice da ily !
One antibiotic, appropriate for treatment for patient age, should be chosen from among the 
alternatives. Treatment with streptomycin, gentamicin, or ciprofloxacin should be continued for 10 
days; treatment with doxycycline should be continued for 14-21 days. Persons beginning 
treatment with intramuscular (IM) or intravenous (IV) doxycycline, ciprofloxacin can switch to oral 
antibiotic administration when clinically indicated.
!N o t a U.S. Food and Drug Administration-approved use.
!Ciprofloxacin dosage should not exceed 1 g/d in children.
Additional information about Tularemia can be found on the CDC website:
<http://www.bt.cdc.gov/agent/tularemia/> http://www.bt.cdc.gov/agent/tularemia/
